Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$172.61
neg -0.53
-0.31%
Today's Range: 171.89 - 174.70 | AMGN Avg Daily Volume: 3,586,600
Last Update: 02/22/17 - 4:00 PM EST
Volume: 2,579,797
YTD Performance: 18.42%
Open: $172.46
Previous Close: $173.14
52 Week Range: $130.09 - $181.81
Oustanding Shares: 736,452,791
Market Cap: 127,619,904,152
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 4 4
Moderate Buy 1 1 1 1
Hold 9 10 11 11
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.16 2.28 2.41 2.41
Latest Dividend: 1.15
Latest Dividend Yield: 2.65%
Dividend Ex-Date: 02/13/17
Price Earnings Ratio: 16.92
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
16.92 16.90 30.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.96% 15.33% 39.80%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.10 0.20 0.07
Net Income 11.30 0.50 0.15
EPS 13.00 0.50 0.15
Earnings for AMGN:
EBITDA 12.03B
Revenue 22.99B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $2.99 $3.10 $12.27 $12.81
Number of Analysts 9 8 12 9
High Estimate $3.11 $3.36 $12.95 $13.73
Low Estimate $2.80 $2.90 $11.81 $12.39
Prior Year $2.90 $2.84 $11.65 $12.27
Growth Rate (Year over Year) 3.14% 9.02% 5.36% 4.39%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA

bullishAmgen estimates, target increased at Oppenheimer

Feb 22, 2017 | 7:24 AM EST
AMGN estimates were raised through 2018, Oppenheimer said. New product approvals and label expansion filings should drive growth. Outperform rating and new $189 price target.
RMPIA
By

Robert Lang

 | Feb 16, 2017 | 11:30 AM EST
There is more upside to come for this stock.
RMPIA
By

Bruce Kamich

 | Feb 16, 2017 | 11:18 AM EST
You might want to review your holdings in the sector.
RMPIA
By

Jim Cramer

 | Feb 15, 2017 | 3:34 PM EST
Some tried-and-true indicators show what's really going on with the market.
RMPIA

bullishAmgen estimates, target increased at BMO

Feb 13, 2017 | 7:28 AM EST
AMGN now seen reaching $212, according to BMO Capital. Estimates also raised, following positive physician and payor feedback. Outperform rating.
RMPIA
By

Mark Sebastian

 | Feb 7, 2017 | 5:22 PM EST
Would get drugs to market faster and possibly more cheaply.
RMPIA
By

Mark Sebastian

 | Feb 7, 2017 | 2:48 PM EST
Getting FDA to streamline its approval process would boost drug makers.
RMPIA
By

James "Rev Shark" DePorre

 | Feb 1, 2017 | 10:51 AM EST
The Fed is simply not a market catalyst this time.
RMPIA
By

Bruce Kamich

 | Jan 23, 2017 | 2:22 PM EST
There's not much reason to be bullish on these stocks.
RMPIA
By

Ed Ponsi

 | Jan 12, 2017 | 10:00 AM EST
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
Here is a well defined zone to look for buy triggers against...defining the risk below it!...
this is the FOURTH big winner we have booked on Apple since December. SOLD AAPL APR 1...
Garmin is the top gainer in the S&P 500 today following this morning's...
Shares of Exxon Mobil  (XOM) have been declining steadily this year, and moved back d...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.